Table 3 Characteristics of the subjects in both groups after crossover and continuation of drug for further 8 weeks
Parameters | mean ± standard deviation (90 % confidence interval) | P-value | |
|---|---|---|---|
1st group (N = 21) | 2nd group (N = 16) | ||
Total cholesterol (mg/dL) | 200.30 ± 36.86 | 182.40 ± 17.24 | NS |
(187.07–213.53) | (175.31–189.49) | ||
HDL (mg/dL) | 47.40 ± 9.64 | 49.40 ± 10.38 | NS |
(43.94–50.86) | (45.13–53.67) | ||
Triglyceride (mg/dL) | 142.40 ± 62.54 | 127.40 ± 58.40 | NS |
(119.95–164.85) | (103.38–151.42) | ||
LDL (mg/dL) | 124.40 ± 31.70 | 107.50 ± 14.65 | NS |
(113.02–135.78) | (101.48–113.52) | ||
SGOT (U/L) | 25.10 ± 7.96 | 23.90 ± 9.50 | NS |
(22.24–27.96) | (19.99–27.81) | ||
SGPT (U/L) | 37.60 ± 22.32 | 30.60 ± 21.79 | NS |
(29.59–45.61) | (21.64–39.56) | ||
CPK (U/L) | 106.20 ± 42.49 | 118.40 ± 42.35 | NS |
(90.95–121.45) | (100.98–135.82) | ||